Take­da antes up $44M for rare dis­ease pact, turn­ing to Ox­ford spin­out's ex­o­some tech

More than two weeks in­to Take­da’s new work guide­lines in re­sponse to the Covid-19 cri­sis — or­der­ing staffers to work from home and stay off the road — the BD team has some­thing to cel­e­brate.

In a boost to the rare dis­ease unit built around Shire’s lega­cy R&D op­er­a­tion af­ter its $62 bil­lion buy­out deal, Take­da has inked a new col­lab­o­ra­tion in pur­suit of ex­o­some de­liv­ery tech­nol­o­gy. Their part­ner of choice is Evox Ther­a­peu­tics, an Ox­ford spin­out.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER